NAD+ — Peptide Protocol Wiki reference

NAD+: Complete Overview and Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About NAD+ 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides NAD+ Anti-Aging & Longevity Cognitive Enhancement Mitochondrial & Cellular Energy phase2 NAD+ Also known as: NAD+, Nicotinamide Adenine Dinucleotide, NAD, Beta-Nicotinamide Adenine Dinucleotide, Coenzyme I, DPN, Diphosphopyridine Nucleotide Compare with 1 peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 12, 2026 Unverified TL;DR NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme found in every living cell, essential for mitochondrial energy production, DNA repair, and cellular signaling.

tivates sirtuins (SIRT1-7) involved in DNA repair, gene silencing, and metabolic regulation • Substrate for PARPs (poly-ADP-ribose polymerases) critical for DNA damage repair • Investigated for neuroprotective effects in neurodegenerative disease models • Modulates inflammatory pathways through CD38 and SARM1 signaling Community-Reported Side Effects Anecdotal ?

📋 Protocol Quick-Reference Anti-aging, cellular energy support, neuroprotection, and metabolic health research 💉 Dosing Amount 250-750 mg per IV session; 300-1000 mg daily for oral precursors (NR/NMN) Frequency 1-2x weekly IV (loading), monthly (maintenance); daily oral Duration 4-8 week loading phase IV; ongoing for oral precursors 💊 Administration Route IV Schedule 1-2 times weekly during loading; monthly maintenance; daily for oral precursors Timing IV sessions require 2-8 hours in clinical setting; oral NR/NMN typically taken in the morning 📅 Cycle Duration 4-8 weeks IV loading; ongoing for oral supplementation Repeatable Yes Preparation & Storage Diluent: Normal saline (0.9% NaCl) 250-500 mL for IV Storage: Lyophilized powder at -20C; reconstituted solution use within 24 hours ⚗️ Suggested Bloodwork ( 5 tests) CMP with liver enzymes (AST, ALT) When: Baseline Why: Baseline hepatic function assessment CBC with differential When: Baseline Why: Baseline hematologic assessment Fasting glucose and insulin When: Baseline Why: Baseline metab

olic assessment Liver enzymes (AST, ALT) When: 4-6 weeks Why: Monitor hepatic function during supplementation NAD+ metabolite panel (if available) When: 4-8 weeks Why: Assess NAD+ response to supplementation 💡 Key Considerations → IV infusion rate determines tolerability; start slow (1-2 mg/min) and titrate → Oral precursors (NR, NMN) bypass the poor oral bioavailability of intact NAD+ → Contraindication: Avoid during active cancer treatment, particularly with PARP inhibitors → Ensure adequate hydration before and during IV sessions Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Restore access No thanks, continue reading Related Reading Comparison Epitalon vs NAD+ comparison Peptide 5-Amino-1MQ NNMT inhibitor that boosts NAD+ levels Article Hallmarks of aging peptide interventions How NAD+ works at the cellular level Overview of NAD+ benefits and applications Scientific Details Molecular Formula C21H27N7O14P2 Molecular Weight 663.43 Da CAS Number 53-84-9 What is NAD+?

# NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that serves as a central metabolic hub linking cellular energy production to signaling and repair processes.

NAD+ exists in two forms: the oxidized form (NAD+) and the reduced form (NADH).

These NAD+-consuming enzymes link cellular metabolic status to epigenetic regulation, DNA repair, calcium signaling, and immune function.

Mechanism of Action # Overview NAD+ functions through two fundamentally different biochemical roles: (1) as a coenzyme in redox reactions, where it shuttles electrons without being consumed, and (2) as a substrate for NAD+-consuming enzymes, where it is cleaved and depleted.

The balance between NAD+ synthesis, consumption, and recycling determines cellular NAD+ availability and, consequently, the activity of NAD+-dependent signaling pathways.

NAD+/NADH ratio: The cytoplasmic NAD+/NADH ratio (~700:1 in well-oxygenated cells) serves as a metabolic sensor, influencing glycolytic flux, gluconeogenesis, and redox-sensitive signaling.

Sirtuin signaling (SIRT1-7) Sirtuins are NAD+-dependent protein deacetylases and ADP-ribosyltransferases that consume NAD+ to remove acetyl groups from target proteins, producing nicotinamide (NAM) and O-acetyl-ADP-ribose.

SIRT1: Nuclear; deacetylates PGC-1alpha (mitochondrial biogenesis), p53 (apoptosis regulation), NF-kB (inflammation), FOXO transcription factors (stress resistance), and histones (epigenetic silencing).

SIRT2: Cytoplasmic/nuclear; deacetylates alpha-tubulin and histones; involved in cell cycle regulation.

NAD+ dependence: Sirtuin activity is directly limited by NAD+ availability; declining NAD+ with age reduces sirtuin function, contributing to mitochondrial dysfunction, epigenetic dysregulation, and impaired stress responses.

It hydrolyzes NAD+ to produce cyclic ADP-ribose (cADRPR) and nicotinamide, regulating intracellular calcium signaling.

CD38 expression increases with age and chronic inflammation, and CD38 has been identified as a major driver of age-related NAD+ decline.

mption pathway relevant to neurodegeneration.

NAD+ biosynthesis pathways De novo synthesis (kynurenine pathway): From dietary tryptophan via quinolinic acid to NAD+; a minor contributor to NAD+ pools in most tissues except the liver.

Preiss-Handler pathway: Converts dietary nicotinic acid (niacin/vitamin B3) to NAD+ via nicotinic acid mononucleotide (NaMN) and nicotinic acid adenine dinucleotide (NaAD+).

Salvage pathway: The predominant route for NAD+ maintenance; recycles nicotinamide (NAM, the byproduct of sirtuin and PARP activity) back to NMN via nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme.

Precursor entry points: Nicotinamide riboside (NR) is phosphorylated by NR kinases (NRK1/2) to NMN, entering the salvage pathway.

ion increased skeletal muscle NAD+ metabolites (NAAD, MeNAM) Anti-inflammatory transcriptomic signatures detected in muscle biopsies Downregulation of energy metabolism and mitochondrial pathways in transcriptome Effect of oral nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men , published in Endocrine Journal (Irie J et al., 2020; DOI: 10.1507/endocrj.EJ19-0313): First-in-human study of oral NMN 250 mg/day in 10 healthy men demonstrating safety and increases in NAD+ metabolites without significant adverse effects NMN 250 mg single dose was safe and well tolerated Increased plasma NMN and NAD+ metabolite levels No clinically significant adverse effects observed NR-SAFE: a randomized, double-blind, placebo-controlled trial of high-dose nicotinamide riboside in healthy middle-aged and older adults , published in Nature Aging (Vreones M et al., 2023): Safety-focused RCT testing NR at 1000 mg twice daily (2000 mg/day) for 12 weeks in healthy adults, establishing safety and tolerability at the highest studied dose NR 2000 mg/day was well tolerated over 12 weeks No clinically significant adverse events attributed to NR Confirmed dose-dependent NAD+ metabolite elevation in blood Nicotinamide riboside supplementation to improve lower extremity function in peripheral artery disease (Kalil RS et al., 2023): RCT investigating NR supplementation in peripheral artery disease patients, representing one of th

Pathway Starting substrate Key enzyme(s) Product Tissue relevance De novo (kynurenine) Tryptophan IDO, TDO, QPRT NAD+ Liver primarily; minor in other tissues Preiss-Handler Nicotinic acid (niacin) NAPRT, NMNATs NAD+ Broad tissue expression Salvage Nicotinamide (NAM) NAMPT (rate-limiting), NMNATs NAD+ Dominant pathway in most tissues NR kinase Nicotinamide riboside (NR) NRK1/2, NMNATs NAD+ Broad; oral supplement route NMN direct NMN NMNATs, Slc12a8 NAD+ Broad; oral supplement route Therapeutic Applications # NAD+ replenishment is being investigated across multiple t

Studies show NAD+ levels decrease by approximately 50% between ages 40 and 60 in some tissues.

In mouse models, NAD+ replenishment via NMN or NR improved mitochondrial function, insulin sensitivity, exercise capacity, and lifespan in some (but not all) genetic backgrounds.

Human clinical trials with NR (NIAGEN) have demonstrated dose-dependent increases in blood NAD+ levels in healthy adults and older individuals.

The Chromadex NIAGEN trials showed sustained elevation of NAD+ at 300-1000 mg/day doses.

Neurodegenerative diseases NAD+ depletion is observed in Alzheimer's disease brain tissue; NMN supplementation improved cognitive function and reduced amyloid pathology in APP/PS1 mouse models.

A Phase II clinical trial (NCT03568968) tested NR in Parkinson's disease patients and reported increases in cerebral NAD+ levels and some improvements in clinical scores.

NR supplementation reduced systemic inflammation and improved vascular endothelial function in a small crossover RCT in healthy middle-aged and older adults.

A pilot study in alcohol use disorder patients found IV NAD+ was safe and showed preliminary improvements in craving and anxiety measures.

Strongest evidence: NR oral supplementation reliably raises blood NAD+ levels in humans (multiple RCTs); safety profile established up to 2000 mg/day.

Moderate evidence: NMN oral supplementation raises NAD+ in humans (emerging RCTs); NR reduces inflammation markers in small trials.

Evidence Gaps and Limitations # The current evidence base has important limitations: Large, long-term randomized controlled trials in disease populations are lacking Optimal dosing, route of administration, and treatment duration have not bee

n established through dose-finding studies Whether raising blood NAD+ translates to meaningful tissue NAD+ increases in humans is incompletely characterized The relative efficacy of different NAD+ precursors (NMN vs NR vs niacin) has not been established in head-to-head trials Long-term safety data beyond 12 months is limited for all NAD+ augmentation strategies Publication bias may favor positive results, particularly in preclinical literature Key Research Findings # Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults , published in Nature Communications (Martens CR et al., 2018; DOI: 10.1038/s41467-018-03421-7): Crossover RCT in 24 healthy older adults showing NR 1000 mg/day for 6 weeks safely raised blood NAD+ by ~60% and tended to reduce systolic blood pressure and aortic stiffness NR 1000 mg/day increased whole blood NAD+ approximately 60% over baseline Trend toward reduced systolic blood pressure (-2 mmHg) and aortic stiffness Well tolerated with no serious adverse events Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures , published in Cell Reports (Elhassan YS et al., 2019; DOI: 10.1016/j.celrep.2019.07.043): Open-label study in 12 aged men showing oral NR 1000 mg/day for 21 days increased skeletal muscle NAD+ metabolome and induced anti-inflammatory gene expression signatures NR supplementat

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme found in every living cell, essential for mitochondrial energy production, DNA repair, and cellular signaling.

What are the benefits of NAD+?